Ascendis Pharma A/S (ASND)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 146.38 |
Market Cap | 9.34B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -6.79 |
PE Ratio (ttm) | -22.99 |
Forward PE | n/a |
Analyst | Buy |
Ask | 166 |
Volume | 736,892 |
Avg. Volume (20D) | 445,942 |
Open | 145.50 |
Previous Close | 144.08 |
Day's Range | 145.00 - 157.10 |
52-Week Range | 111.09 - 161.00 |
Beta | undefined |
About ASND
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops Tra...
Analyst Forecast
According to 14 analyst ratings, the average rating for ASND stock is "Buy." The 12-month stock price forecast is $186, which is an increase of 19.15% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
Why Price Moved
News

1 week ago · accessnewswire.com
Ascendant Resources Announces Closing of First Tranche of Private Placement• Funds to Progress Lagoa Salgada Project and extinguish a significant portion of short-term payables • Additional Support Received for Arrangement with Cerrado NOT FOR DISTRIBUTION TO U.S. NEWS WIRE ...